Comment & Sign-on Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Access to Care & Reimbursement

Support for legislation that would improve patients’ access to care

PAN Patient Community HHS Blueprint Letter (July 16, 2018)

REAP Coalition HHS Blueprint Letter (July 16, 2018)

CSC HHS Blueprint Letter (July 15, 2018)

LUNGevity Comments on Guardant360 LCD – May 2018 (May 9, 2018)

Cancer Care Planning and Communication Act, H.R. 5160 (March 14, 2018)

Right to Try Coalition Letter (House) (March 12, 2018)

Right to Try (S.204 & H.R. 878) (February 6, 2018)

LUNGevity NGS National Coverage Determination Comments to CMS (January 17, 2018)

LUNGevity CMMI 2017 RFI Comments (November 20, 2017)

REAP Coalition CMMI 2017 RFI (November 20, 2017)

Veterans Affairs ICER Letter (November 13, 2017)

MassHealth 1115 Waiver Letter 2017 (October 18, 2017)

340B Drug Discount Program (September 27, 2017)

Sign-On HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 11, 2017)

LUNGevity HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 7, 2017)

Guardant360 LCD 2017 (July 19, 2017)

Medicaid Expansion and Per Capita Caps (June 15, 2017)

Letter on Patient Protection and Affordable Care Act; Market Stabilization (March 7, 2017)

Regence reimbursement policy letter (February 14, 2017)

Letter to House (February 6, 2017)

Letter to Senate (February 6, 2017)

Joint letter to Congress (February 2, 2017)

Comment on ICER blog

Letter on ICER draft document for NSCLC (September 15, 2016)

Partnership to Improve Patient Care ICER letter (September 12, 2016)

Letter to CMS supporting screening (October 8, 2014)

Food and Drug Administration (FDA)

Support for FDA appointment nominees and initiatives to streamline the cancer drug approval process

Oncology Center of Excellence (OCE) (August 3, 2017)

Enhancing Patient Engagement Efforts Across FDA (June 12, 2017)

Coalition for Clinical Trials Awareness letter (April 7, 2017)

Gottlieb support letter (April 4, 2017)

Gottlieb support letter (March 13, 2017)

Friends of the Cancer Policy Institute letter (January 31, 2017)

Oncology Center for Excellence letter (June 6, 2016)

Califf support letter (February 19, 2016)

Diagnostics Testing Regulation

Urging policymakers to include FDA involvement in the regulation of lab-developed tests

Diagnostic Reform Coalition Letter – May 2018 (May 9, 2018)

Letter to the House on Regulation of Lab-Developed Tests (January 24, 2017)

Letter to the Senate on Regulation of Lab-Developed Tests (January 24, 2017)

Letter to House on Regulation of Lab-Developed Tests (April 1, 2016)

Letter to Senate on Regulation of Lab-Developed Tests (April 1, 2016)

Federal Research Funding

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate (November 16, 2016)

print